| 发明名称 |
ANTI-IL-4/ANTI-IL-13 BISPECIFIC ANTIBODY FORMULATIONS |
| 摘要 |
The present invention provides stable pharmaceutical antibody formulations, including lyophilized formulations, comprising an anti-IL-4/anti-IL-13 bispecific antibody and a buffering system, wherein the pH of the formulation is about pH 7, and wherein the formulation has a low salt concentration in order to reduce the ionic strength of the formulation. The formulations may, optionally, further comprise a non-ionic surfactant, a sugar, and/or a non-ionic stabilizing agent. The formulations can be used in the treatment of various diseases. |
| 申请公布号 |
US2016075777(A1) |
申请公布日期 |
2016.03.17 |
| 申请号 |
US201414787507 |
申请日期 |
2014.04.29 |
| 申请人 |
SANOFI |
发明人 |
Carayon Sophie;Boussif Otmane |
| 分类号 |
C07K16/24;A61K47/22;A61K47/26;C07K16/46;A61K39/395 |
主分类号 |
C07K16/24 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A stable antibody formulation comprising:
a bispecific anti-IL-4/anti-IL-13 antibody or an antigen binding fragment thereof, comprising a light chain of the formula VL1-linker-VL2 and a heavy chain of the formula VH1-linker-VH2, wherein VL1 and VH1 form an IL-13 antigen binding domain and VL2 and VH2 form an IL-4 antigen binding domain; and a buffering system suitable to maintain the pH of the formulation at about pH 7; and wherein the formulation has a low salt concentration in order to reduce the ionic strength of the formulation. |
| 地址 |
Paris FR |
